Ignite Creation Date:
2025-12-26 @ 4:02 PM
Ignite Modification Date:
2026-01-25 @ 6:08 AM
Study NCT ID:
NCT00013806
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-03-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
Sponsor:
National Center for Research Resources (NCRR)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
NCRR-M01RR00240-1748
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None